In today’s ACT Brief, we cover the FDA approval of oral Wegovy based on Phase III OASIS 4 results, recap the most-read ...
Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with ...
Generative AI adoption, regulatory scrutiny, DEI policy shifts, real-world evidence, and rare disease economics emerged as key themes across these most-read Applied Clinical Trials articles shaping ...
Review the performance, engagement, and satisfaction metrics sponsors and CROs should track to determine whether operational ...
If we can use AI or AI agents to automate those workflows, you can still run the same process, particularly as it relates to ...
Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, outperforming placebo. The FDA approval of oral semaglutide marks the first GLP-1 pill for chronic weight management, ...
In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor ...
Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, ...
In today’s ACT Brief, we look at emerging operational changes aimed at reducing site burden, review the FDA approval of GSK’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback